We narrowed to 2,439 results for: hal.2
-
Viral Prep#117382-AAV9PurposeReady-to-use AAV9 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.DepositorPromoterSynTagseYFPAvailable SinceJan. 6, 2022AvailabilityAcademic Institutions and Nonprofits only
-
pAAV-hSyn1-eYFP (AAV8)
Viral Prep#117382-AAV8PurposeReady-to-use AAV8 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.DepositorPromoterSynTagseYFPAvailable SinceJan. 6, 2022AvailabilityAcademic Institutions and Nonprofits only -
pAAV-hSyn1-eYFP (AAV1)
Viral Prep#117382-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.DepositorPromoterSynTagseYFPAvailable SinceAug. 15, 2025AvailabilityAcademic Institutions and Nonprofits only -
pAAV-CAG-eYFP (AAV5)
Viral Prep#104055-AAV5PurposeReady-to-use AAV5 particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsEYFPAvailable SinceSept. 27, 2023AvailabilityAcademic Institutions and Nonprofits only -
pAAV-TRE-DIO-eYFP (AAV1)
Viral Prep#117383-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-TRE-DIO-eYFP (#117383). In addition to the viral particles, you will also receive purified pAAV-TRE-DIO-eYFP plasmid DNA. Tet-inducible, Cre-dependent eYFP expression. These AAV preparations are suitable purity for injection into animals.DepositorPromoterTRETagseYFP (Tet-inducible, Cre-dependent)Available SinceJan. 6, 2022AvailabilityAcademic Institutions and Nonprofits only -
pAAV-hSyn1-eYFP (AAV Retrograde)
Viral Prep#117382-AAVrgPurposeReady-to-use AAV Retrograde particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.DepositorPromoterSynTagseYFPAvailable SinceOct. 18, 2021AvailabilityAcademic Institutions and Nonprofits only -
pAAV-hSyn1-eYFP (AAV PHP.eB)
Viral Prep#117382-PHPeBPurposeReady-to-use AAV PHP.eB particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.DepositorPromoterSynTagseYFPAvailable SinceJan. 6, 2022AvailabilityAcademic Institutions and Nonprofits only -
pAAV-CAG-eYFP (AAV Retrograde)
Viral Prep#104055-AAVrgPurposeReady-to-use AAV Retrograde particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsEYFPAvailable SinceJan. 6, 2022AvailabilityAcademic Institutions and Nonprofits only -
pAAV-CAG-eYFP (AAV PHP.eB)
Viral Prep#104055-PHPeBPurposeReady-to-use AAV PHP.eB particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsEYFPAvailable SinceJune 13, 2023AvailabilityAcademic Institutions and Nonprofits only -
pAAV-CAG-NLS-GFP (AAV PHP.eB)
Viral Prep#104061-PHPeBPurposeReady-to-use AAV PHP.eB particles produced from pAAV-CAG-NLS-GFP (#104061). In addition to the viral particles, you will also receive purified pAAV-CAG-NLS-GFP plasmid DNA. CAG-driven NLS-GFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsGFPAvailable SinceMarch 5, 2019AvailabilityAcademic Institutions and Nonprofits only -
pLVX-EF1alpha-SARS-CoV-2-nsp5-C145A-2xStrep-IRES-Puro
Plasmid#141371PurposeLentiviral expression of SARS-CoV-2 protein; transient expression and generate lentivirusDepositorInsertSARS-CoV-2-nsp5-C145A (ORF1ab SARS-CoV-2)
UseLentiviralTags2xStrepExpressionMammalianMutationC145A, human codon optimizedPromoterEF1alphaAvailable SinceApril 6, 2020AvailabilityIndustry, Academic Institutions, and Nonprofits -
pAAV-CAG-DIO-EYFP (AAV PHP.V1)
Viral Prep#104052-AAVPHP.V1PurposeReady-to-use AAV PHP.V1 particles produced from pAAV-CAG-DIO-EYFP (#104052). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-EYFP plasmid DNA. CAG-driven, Cre-dependent expression of EYFP. These AAV were produced with the PHP.V1 serotype, which permits efficient transduction of brain vascular cells. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsEYFP (Cre-dependent)Available SinceJuly 24, 2020AvailabilityAcademic Institutions and Nonprofits only -
R619-M67-303: CMV51p> SARS-CoV-2 S-RBD(319-541)-His6
Plasmid#166018Purposemammalian expression of SARS-CoV-2 spike receptor-binding domain (RBD)DepositorAvailable SinceMarch 11, 2021AvailabilityAcademic Institutions and Nonprofits only -
R620-M07-303: CMV51p> TPAss-SARS-CoV-2 S-RBD(319-541)-His6 E484K
Plasmid#170193PurposeMammalian expression of SARS-CoV-2 spike receptor-binding domain (RBD), E484K mutantDepositorAvailable SinceMay 11, 2022AvailabilityAcademic Institutions and Nonprofits only -
pJT342 Lenti pEF-dCas9-3XFLAG-RYBP + MGA1+2-T2A-tagBFP-P2A-Blast
Plasmid#195541PurposedCas9 effector fusion for manipulating transcriptionDepositorInsertLenti pEF-dCas9-3XFLAG-RYBP + MGA1+2-T2A-tagBFP-P2A-Blast
UseCRISPR and LentiviralTags3XFLAGExpressionMammalianPromoterpEF1aAvailable SinceMay 6, 2024AvailabilityAcademic Institutions and Nonprofits only -
R620-M08-303: CMV51p> TPAss-SARS-CoV-2 S-RBD(318-529)-3C-His8-SBP E484K
Plasmid#170194PurposeMammalian expression of SARS-CoV-2 spike receptor-binding domain (RBD), E484K mutantDepositorInsertSARS-CoV-2 RBD (S SARS-CoV-2)
Tags3C-His8-SBPExpressionMammalianMutationE484KPromoterCMV51Available SinceMay 11, 2022AvailabilityAcademic Institutions and Nonprofits only -
R620-M03-303: CMV51p> TPAss-SARS-CoV-2 S-RBD(319-541)-His6 N501Y
Plasmid#170189PurposeMammalian expression of SARS-CoV-2 spike receptor-binding domain (RBD), N501Y mutant from B.1.1.7 variantDepositorAvailable SinceMay 11, 2022AvailabilityAcademic Institutions and Nonprofits only -
R620-M06-303: CMV51p> TPAss-SARS-CoV-2 S-RBD(319-529)-3C-His8-SBP K417N/E484K/N501Y
Plasmid#170192PurposeMammalian expression of SARS-CoV-2 spike receptor-binding domain (RBD), triple mutant from B.1.351 variantDepositorInsertSARS-CoV-2 RBD (S SARS-CoV-2)
Tags3C-His8-SBPExpressionMammalianMutationK417N, E484K, N501YPromoterCMV51Available SinceMay 11, 2022AvailabilityAcademic Institutions and Nonprofits only -
R620-M04-303: CMV51p> TPAss-SARS-CoV-2 S-RBD(318-529)-3C-His8-SBP N501Y
Plasmid#170190Purposeammalian expression of SARS-CoV-2 spike receptor-binding domain (RBD), N501Y mutant from B.1.1.7 variantDepositorInsertSARS-CoV-2 RBD (S SARS-CoV-2)
Tags3C-His8-SBPExpressionMammalianMutationN501YPromoterCMV51Available SinceMay 11, 2022AvailabilityAcademic Institutions and Nonprofits only -
R620-M18-303: CMV51p> SARS-CoV-2 S-RBD(319-541)-His6 K417T/E484K/N501Y
Plasmid#170202PurposeMammalian expression of SARS-CoV-2 spike receptor-binding domain (RBD), N501Y mutant from B.1.1.28 variantDepositorInsertSARS-CoV-2 RBD (S SARS-CoV-2)
TagsHis6ExpressionMammalianMutationK417T, E484K, N501YPromoterCMV51Available SinceMay 11, 2022AvailabilityAcademic Institutions and Nonprofits only